GRNOPC1: IND resumed

FDA lifted the clinical hold placed on an IND for a U.S. Phase I trial of GRNOPC1 to treat acute spinal cord injury. The trial for the human embryonic stem cell (hESC)-derived oligodendrocytes is expe...